Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roland Schnell

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Expert Opinion on Investigational Drugs|July 30, 2005
The role of pixantrone in the treatment of non-Hodgkin's lymphomaPeter Borchmann, Roland Schnell
Current Opinion in Molecular Therapeutics|April 14, 2006
SGN-30 (Seattle genetics)Roland Schnell, Peter Borchmann
Current Opinion in Investigational Drugs (London, England : 2000)|January 15, 2005
Monoclonal antibody-based immunotherapy of Hodgkin's lymphomaPeter Borchmann, Roland Schnell, Holger Schulz, et al.
Haematologica|December 7, 2005
Current treatment and immunotherapy of Hodgkin's lymphomaBeate Klimm, Roland Schnell, Volker Diehl, et al.
The Cochrane Database of Systematic Reviews|October 19, 2012
First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studiesFrauke Naumann-Winter, Alexander Greb, Peter Borchmann, et al.
Onkologie|February 13, 2008
Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin's LymphomaRoland Schnell, Markus Dietlein, Klaus Schomäcker, et al.
Lung Cancer (Amsterdam, Netherlands)|September 17, 2017
Treatment, outcome and quality of life of 1239 patients with advanced non-small cell lung cancer - final results from the prospective German TLK cohort studyUlla von Verschuer, Roland Schnell, Hans Werner Tessen, et al.
Blood|October 17, 2007
Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)Holger Schulz, Ute Rehwald, Franck Morschhauser, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2002
A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphomaRoland Schnell, Oliver Staak, Peter Borchmann, et al.
Blood|October 18, 2002
Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphomaPeter Borchmann, Roland Schnell, Irene Fuss, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Expert Opinion on Investigational Drugs|July 30, 2005
The role of pixantrone in the treatment of non-Hodgkin's lymphomaPeter Borchmann, Roland Schnell
Current Opinion in Molecular Therapeutics|April 14, 2006
SGN-30 (Seattle genetics)Roland Schnell, Peter Borchmann
Current Opinion in Investigational Drugs (London, England : 2000)|January 15, 2005
Monoclonal antibody-based immunotherapy of Hodgkin's lymphomaPeter Borchmann, Roland Schnell, Holger Schulz, et al.
Haematologica|December 7, 2005
Current treatment and immunotherapy of Hodgkin's lymphomaBeate Klimm, Roland Schnell, Volker Diehl, et al.
The Cochrane Database of Systematic Reviews|October 19, 2012
First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studiesFrauke Naumann-Winter, Alexander Greb, Peter Borchmann, et al.
Onkologie|February 13, 2008
Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin's LymphomaRoland Schnell, Markus Dietlein, Klaus Schomäcker, et al.
Lung Cancer (Amsterdam, Netherlands)|September 17, 2017
Treatment, outcome and quality of life of 1239 patients with advanced non-small cell lung cancer - final results from the prospective German TLK cohort studyUlla von Verschuer, Roland Schnell, Hans Werner Tessen, et al.
Blood|October 17, 2007
Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)Holger Schulz, Ute Rehwald, Franck Morschhauser, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2002
A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphomaRoland Schnell, Oliver Staak, Peter Borchmann, et al.
Blood|October 18, 2002
Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphomaPeter Borchmann, Roland Schnell, Irene Fuss, et al.
Pageof 3